Oral Menopausal Hormone Therapy Linked to Higher Blood Clot Risk
A Danish registry analysis finds clot risks with oral treatment while skin patches and gels avoid general increases.
Study Analyzes Nationwide Records on Menopausal Hormone Therapy
Current use of oral menopausal hormone therapy, commonly called hormone replacement therapy (HRT), is associated with a higher risk of blood clots in the legs or lungs regardless of dose or duration.
Researchers analyzed Danish health registry data collected between 2003 and 2021 for women aged 50 to 69 who experienced a first venous thromboembolism, ischemic stroke, or heart attack.
The observational analysis evaluated 9,807 women with venous thromboembolism, 18,460 with ischemic stroke, and 11,974 with heart attack against matched control participants without thrombotic disease.
Oral Menopausal Hormone Therapy Linked to Higher Blood Clot Risk
Oral estrogen treatment produced measurable annual increases in venous thromboembolism, ischemic stroke, and heart attack across the evaluated cohort.
Among women unexposed to hormone therapy, baseline rates were 15.8 for venous thromboembolism, 20.3 for ischemic stroke, and 13.0 for heart attack per 10,000 person-years.
Oral treatment resulted in absolute yearly increases of 0.09 percent for venous thromboembolism, 0.06 percent for stroke, and 0.03 percent for heart attack, which reflects one extra blood clot case per 1,055 women treated for one year.
Transdermal Hormone Treatments Avoid General Clot Increases
Transdermal hormone therapy administered through patches, gels, or sprays showed no general increased blood clot risk regardless of regimen, dose, or duration.
Risks for ischemic stroke and heart attack on oral regimens were confined to individuals taking high-dose oral estradiol above 1 milligram per day for more than one year.
The investigators recorded an elevated heart attack rate for combined transdermal cyclic regimens where progestogen is added cyclically, though the authors note this specific finding rests on sparse data.
Study Design Caveats and Unmeasured Risk Factors
The observational design of the Danish registry study cannot establish direct cause and effect.
Registry files lacked information on participant body mass index (BMI), smoking status, and exact age at menopause.
The authors also note that these findings from a Danish population sample may not apply directly to more ethnically diverse populations.
Related Articles
Early Menopausal Transition Linked to Higher Anxiety and Depression
Data from the Northern Finland Birth Cohort 1966 links early menopausal transition at age 46 to...
Read article HormonesACP Recommends Hormonal Therapy as First-Line Care for Menopause
The American College of Physicians recommends hormonal therapy as the first-line treatment for...
Read article HormonesHealth Behavior Change in PCOS Follows a Nonlinear Path
A qualitative study in the Journal of Nutrition Education and Behavior maps how women with PCOS...
Read article HormonesHuman Pituitary Tissue Transplant Restores Primate Hormone Levels
Nagoya University researchers transplanted stem cell-derived human pituitary tissue into a...
Read articlePartner · Opt Health
Want a clinician who takes perimenopause seriously?
Opt Health's women's program runs full hormone and thyroid panels and treats the symptoms most primary-care visits wave off — sleep, mood, energy, cycle changes, libido — with physicians trained in hormone medicine.
See Opt Health's women's program →Topic updates
Get the weekly hormone optimization roundup
Testosterone, thyroid, cortisol, estrogen, menopause, perimenopause, libido, and hormone testing.
Understand Your Health Better
Our free assessment maps your symptoms to the most relevant guides, tools, and product recommendations.
Take the Free Assessment →Free · Takes 5 minutes · Instant results